inc headquart danver
lead provid medic devic design use
primarili use either cardiac catheter
lab cath lab intervent cardiologist
heart surgeri suit cardiovascular surgeon
patient receiv devic need
prophylact hemodynam support high-risk
angioplasti procedur experienc pre-shock
shock profound cardiogen shock
reason report
estim chang recap compani visit
maintain o/v invest rate
price target share modestli reduc former
million revenu estim million million
lower bound corpor guidanc reflect heighten
conservat associ near-term outlook follow
question public circul clear view
circul articl clinic merit remain view
ultim success re-acceler corpor growth
howev continu acknowledg near-term
tempor headwind like constrain corpor growth throughout
fh simpli put near-
term remain challeng long-term growth potenti remain
headquart visit recent host investor lunch
danver massachusett headquart chairman
offic todd trapp vice-president chief commerci offic andrew
share remain unchang recal price target impli
revenu multipl approxim
chang estim fine-tun revenu
earn estim million per share
million per share likewis fine-tun
former million per share earn estim
billion per share respect
valuat summari share current valu ev/
revenu versu compar peer trade like multipl
admittedli share still possess notabl rel
premium view merit base compani larg
exist effect monopoli busi model top tier
gross oper margin profil profit debt free
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
topic discuss lunch meet investor well ceo michael minogu focus
recent present data circul argu intra-aort balloon pump better outcom compar
impella recal paper initi present aha present retrospect propens
match in-hospit review payer code data
brine togeth circul observ analysi creat yet anoth headwind overcom
marketplac nearer-term opinion compani ultim success address issu rais
time basic educ clinic data addit eas use issu non tavr oper
absolv advent ecp slate commenc regulatori march lastli end
market remain significantli under-penetrated independ potenti expans result stemi-
dtu studi result look success effect restor top-quartil organ revenu growth
top echelon gross oper margin compani exit challeng immedi short-term
see opportun signific capit appreci impella potenti becom standard care case pci
long-term result reiter o/v invest rate abmd share
circul lunch began discuss recent non-fda audit observ analysi evolv
landscap impella use unit state among patient undergo percutan coronari intervent
mechan circulatori support publish novemb issu circul retrosprect analysi
base code data rather actual outcom data collect six hospit major high ecmo
user premier healthcar data base moreov note conclus base impella
case last year paper conclud increas usag impella pci result higher rate
complic cost conclus run counter publish clinic literatur fda studi date
critiqu opinion piec note author combin elect urgent case make proper propens
match imposs second data set select depict impella patient materi sicker baselin
present greater procedur risk lastli report exclud impella patient escal addit therapi
signific driver cost benefit simpli put view opinion express author base
sound propspect fda-audit clinic data publish readili avail consist
natur yet despit note fundament flaw face nois marketplac
salesforc must success work address assert rais educ hard clinic data
comparison appropri sound note cursori review author summari patient
characterist tabl readili depict materi differ impella iabp patient popul end note
impella patient diabet versu iabp patient impella patient
congest heart failur versu iabp patient impella patient chronic renal failur
versu iabp patient impella patient multi vessel diseas versu iabp patient
impella patient nstemi versu iabp patient simpli put opinion
mean propens match data set
higher mortal risk histor shock patient low chanc surviv per literatur impella
usag serv increas surviv rate rang note inova ncsi databas
result keep author conclus
higher rate advers event author assert use impella result increas macc howev
fda-audit result note protect ii protect come differ conclus recal protect
ii impella use associ composit macc rate day versu iabp use result
macc rate clearli impella usag result reduct advers event likewis protect
impella macc rate declin also case sub-studi analysi protect
acut kidney injuri aki analysi predict aki rate actual aki rate impella usag
impella cp simpli put impella usag serv reduc aki increas associ risk
bleed major complic impella publish fda data bleed complic depict impella
incid bleed complic versu iabp tandemheart fda random
control trial rct meta-analysi ecmo simpli put data support author
circul articl conclus relat bleed relat complic
money author assert impella usag result higher patient cost howev
born real world studi end cite cross-sect studi nation trend
util short-term mechan circulatori support publish jacc depict averag cost per
patient declin
thought expand util discuss note commun hospit realiz need
impella often lack appropri structur place success offer devic result work
appropri educ train oper also support staff appropri use compani
address market dedic specialti team smaller focus past train
support bolster advent smartassist facilit real-tim monitor impella patient addit
focu center eas use issu anticip exist ecp enter marketplac
end recal compani plan first use ecp come march/april time-frame total
encourag abmd effort address untap potenti note add take time come
lower volum return convert
consolid statement incom
dollar thousand except per share data
product revenu
research develop
sell gener administr
total incom expens
fiscal period
fiscal period
incom continu oper tax
tax incom continu oper
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
